Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.

PubWeight™: 0.82‹?›

🔗 View Article (PMID 26169396)

Published in Antimicrob Agents Chemother on July 13, 2015

Authors

Vincent P DeMarco1, Alvaro A Ordonez1, Mariah Klunk1, Brendan Prideaux2, Hui Wang3, Zhang Zhuo3, Peter J Tonge3, Robert F Dannals4, Daniel P Holt4, Carlton K K Lee5, Edward A Weinstein6, Véronique Dartois2, Kelly E Dooley7, Sanjay K Jain8

Author Affiliations

1: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
2: Public Health Research Institute Center, New Jersey Medical School-Rutgers, Newark, New Jersey, USA.
3: Institute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York, USA.
4: Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
5: Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
6: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
7: Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
8: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA sjain5@jhmi.edu.

Articles cited by this

Ipr1 gene mediates innate immunity to tuberculosis. Nature (2005) 4.53

Tuberculous pericarditis. Circulation (2005) 4.09

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis (2012) 3.86

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2003) 3.76

Molecular imaging in drug discovery and development. Nat Rev Drug Discov (2003) 3.44

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis (2012) 2.60

Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis (2013) 2.29

Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18

Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96

Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Sci Transl Med (2014) 1.94

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother (2007) 1.93

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86

Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med (2011) 1.80

Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 1.66

Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 1.64

High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem (2011) 1.64

Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) (2010) 1.54

MSiReader: an open-source interface to view and analyze high resolving power MS imaging files on Matlab platform. J Am Soc Mass Spectrom (2013) 1.51

Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother (2014) 1.41

Pathogenesis of central nervous system tuberculosis. Curr Mol Med (2009) 1.22

Tuberculosis therapy: past, present and future. Eur Respir J Suppl (2002) 1.20

Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb) (2008) 1.10

Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08

Antibiotic dosing in critical illness. J Antimicrob Chemother (2011) 1.05

Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS (2013) 1.04

PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med (2014) 1.02

Approaches using molecular imaging technology -- use of PET in clinical microdose studies. Adv Drug Deliv Rev (2010) 0.97

Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother (2014) 0.96

Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother (2012) 0.96

Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin Pharmacokinet (2002) 0.92

Methods to assess tissue-specific distribution and metabolism of drugs. Curr Drug Metab (2004) 0.91

Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol (2013) 0.90

Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem (2010) 0.90

In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens. Curr Pharm Des (2011) 0.90

Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713. J Infect Dis (2013) 0.89

PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des (2001) 0.88

Update on tuberculosis of the central nervous system: pathogenesis, diagnosis, and treatment. Clin Chest Med (2009) 0.87

Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis. J Commun Dis (1997) 0.87

The evolution of imaging in cancer: current state and future challenges. Semin Oncol (2011) 0.87

18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series. BMC Pulm Med (2013) 0.86

Imaging Chronic Tuberculous Lesions Using Sodium [(18)F]Fluoride Positron Emission Tomography in Mice. Mol Imaging Biol (2015) 0.81

Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development. Bioanalysis (2010) 0.78